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Thomas Brick1* and Mark J Peters1,2Abstract
Severe anemia contributes significantly to child mortality in sub-Saharan Africa. Blood transfusion is used in emergencies
but carries risks. In BMC Medicine, Olupot-Olupot and colleagues report the findings of a phase II trial in children with
severe anemia in Eastern Uganda. They provide important early safety and efficacy data supporting large volume whole
blood transfusion (30 ml/kg) compared with the World Health Organization recommendation of 20 ml/kg. Large volume
transfusions result in more rapid and frequent correction of severe anemia; they can be expected to reduce the risk of
transfusions, and help manage the scarce resource of donor blood. However, severe anemia arises from varying
combinations of acute, sub-acute and chronic etiologies.
The Fluid Expansion As Supportive Therapy study reminds us that the risks and benefits of even simple interventions
are complex, and that rapid normalization of physiology may not always be the best strategy. There is no substitute for
high quality evidence and to this end we strongly support Olupot-Oluput and colleagues’ call for a definitive trial of
large volume transfusions in severe anemia.
Please see related research article http://www.biomedcentral.com/1741-7015/12/67/abstract.
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An estimated 6.6 million children died worldwide in
2012. The highest rates of child mortality are found in
sub-Saharan Africa where 98 per 1,000 children die
before the age of five. This represents nearly half of the
global deaths in children under five. Child mortality has
fallen by 45% since 1990, although at projected rates of
decrease, the Millennium Development Goal Four - a
two-thirds reduction in the under-five mortality rate by
2015 - will not be met [1].
Anemia is responsible for 11% to 14% of childhood
deaths in highly malarious regions of sub-Saharan Africa
[2]. Between 12% and 29% of children admitted to hospital
in these areas are severely anemic [3] (often defined as a
hemoglobin level <5 g/dL). The outcomes for severe
anemia are poor: in-hospital mortality is between 6%
and 16% [4-7] with a longer-term mortality of 13% to
30% [5,8]. The etiology of severe anemia varies by region;* Correspondence: thomas.brick@gmail.com
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2014malaria predominates in endemic areas. Other contributing
factors include malnutrition, vitamin deficiency and
infections with bacteria, human immunodeficiency virus
(HIV), hookworm and schistosomiasis. The interaction
between these risk factors is complex [3,9].
Blood transfusion in sub-Saharan Africa
Blood transfusion increases short-term survival from se-
vere anemia with respiratory distress [4,8] but two thirds
of deaths occur before a blood transfusion is administered
[10]. There is currently no evidence of a long-term sur-
vival benefit of transfusion. This may reflect difficulty in
addressing the underlying parasitemia, bacterial infection
or malnutrition, or might mean that current transfusion
practice is sub-optimal [4,8].
Large volume blood transfusions
In a recent phase II trial published in BMC Medicine,
Olupot-Olupot and colleagues provide a welcome step
towards obtaining a definitive answer on the choice of
blood transfusion volumes in severe anemia in sub-Saharan
Africa [11].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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data of a large volume transfusion (30 ml/kg) of whole
blood in children with severe anemia in comparison to
the current World Health Organization (WHO) guideline
of 20 ml/kg [12]. The children in this study were sick: half
were in respiratory distress, one third were prostrate and
one third had a blood lactate level >5 mmol/l. All received
a bundle of standard care. The large volume transfusion
arm demonstrated more frequent correction and higher
resultant hemoglobin than the 20 ml/kg arm; an effect
that was sustained at 48 hours, although not at 28 days.
At 28 days, the overall mortality was 4%. This compares
favorably with 8% to 30% case fatality in other studies
[4,8], and supports rapid access to transfusion and a stan-
dardized bundle of care in children with severe anemia in
sub-Saharan Africa.
The risk-benefit relationship for blood transfusion
The justification for this study is two-fold: full resuscita-
tion is likely to be more effective than partial resuscitation,
but - perhaps more importantly - multiple transfusions in
this environment are problematic. Blood transfusion in
sub-Saharan Africa carries risks and is a scarce resource.
Under-resourced laboratory facilities and poorly trained
clinical and laboratory staff contribute to this risk. The last
decade has seen the introduction of national transfusion
services with the aim of ensuring a supply of ‘safe blood’.
The impact of these changes is not fully understood
and the provision of safe blood remains a considerable
challenge [13]. Viral transmission rates from blood
transfusion in sub-Saharan Africa are significant. The
risks of HIV, hepatitis B virus and hepatitis C virus in-
fection are estimated at 1, 4.3 and 2.5 cases per 1,000
units of blood transfused, respectively [14]. Blood is
frequently unavailable, and therefore is often donated
as an emergency for urgent transfusion [15]. The WHO
guidance on blood transfusion promotes the rational use
of this scarce, and potentially dangerous, resource by
advocating a restrictive approach to blood transfusion
in severe anemia [12].
Increasing the volume of blood transfusion from a
single donor is therefore a potentially important strategy.
It offers the possibility of increasing the efficacy of transfu-
sion without the additional risk of multiple donor expo-
sures and opportunities for errors. Olupot-Olupot et al.
[11] observed an increased efficacy of transfusion (90% of
children have anemia corrected by 24 hours with 30 ml/kg
versus 74% with 20 ml/kg; risk ratio (RR) 1.54, 95% confi-
dence interval (CI) 1.09, 2.18) alongside a trend towards a
reduction in meeting criteria for subsequent transfusion
(RR 0.35, 95% CI 0.12, 1.04). A trend towards reduced
early (<48 hour) and 28-day mortality is encouraging.
This combination of results makes a powerful case for
a definitive trial.Should practice change on these data alone? After all,
there is a sound physiological basis for improving oxygen
delivery by raising hemoglobin whilst minimizing the risks
of treatment. We suggest that the answer is ‘not yet’. This
caution arises, perhaps ironically, from the same group’s
previous work. The unexpected results of the remarkable
Fluid Expansion as Supportive Therapy (FEAST) study
[16] - in which volume expansion was inferior to ‘no
bolus’ for children with severe febrile illness - may well be
relevant. At the very least these results caution against de-
riving treatment strategies by simply correcting physio-
logical variables. A process of protective physiological
adaption may have taken place in response to disease over
acute, sub-acute or chronic time-scales and rapid correc-
tion of physiological variables must be undertaken with
caution. Supplementary analysis of the FEAST data has re-
vealed the finding that excess mortality due to rapid boluses
of intravenous fluids was primarily due to cardiovascular
collapse, not cerebral edema or congestive heart failure as
had been anticipated [17]. In environments without ready
access to oxygen, continuous positive pressure ventilation
or inotropic support, the principle of cautious physiological
correction applies perhaps more strongly than elsewhere.
Olupot-Olupot et al. understand the need for close
monitoring for fluid overload; indeed, clinical signs of
fluid overload were specified as a serious adverse event
(SAE). It is reassuring that SAEs were not greater in the
30 ml/kg group and that none of the seven fatal events
were recorded as being due to heart failure. However,
the mechanism by which blood transfusion is beneficial
whilst volume expansion is detrimental in sick children
with anemia still needs to be elucidated.
Conclusions
The threshold at which to transfuse blood in children
with severe anemia in sub-Saharan Africa is determined
by a number of factors that affect the risk-benefit relation-
ship. Some of these can potentially be quantified: the risk
of viral transmission through blood, the more general
risks of blood transfusion, the risk of rapid volume expan-
sion in the critically ill child, the risk of small volume
transfusion not achieving benefit, the resource cost of a
transfusion service, and the opportunity cost of foregoing
alternative healthcare interventions. We can, cautiously,
hypothesize that the benefit of transfusion increases both
as the child’s hemoglobin falls and when severe anemia is
accompanied by severe physiological derangement. The
risk-benefit relationship of transfusion is likely to be con-
text specific, and will be influenced by region, etiology of
severe anemia and accompanying disease. The complexity
of these factors is such that definite empirical data from a
large-scale phase III trial is the way forward. Oluput-
Oluput and colleagues have moved this closer with their
important study.
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